Affordable Prescriptions for Patients Act of 2023

1/2
Status Received in Chamber
Sponsor John Cornyn
Citation 118-S-150
Actions 10
Introduced Jan 30th, 2023
Cosponsors
4 4
Last Action Jul 15th, 2024
Policy Area
✓
Introduced Senate Jan 30
✓
Senate Passed Jul 11
House
President
Enacted

Summary

AI Guide

What this bill does

Loading AI analysis…

Affordable Prescriptions for Patients Act of 2023 This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.  

Actions

10
Senate House
INTRODUCED
INTRODUCED
Jan 30, 2023
ON FLOOR
REFERRED TO COMMITTEE
COMMITTEE
COMMITTEE ORDERED TO REPORT
Feb 9, 2023
COMMITTEE
COMMITTEE REPORT FILED UNAMENDED
Mar 1, 2023
PLACED ON CALENDAR
PLACED ON CALENDAR
ON FLOOR
LAID BEFORE CHAMBER BY UNANIMOUS CONSENT
Jul 11, 2024
ON FLOOR
VOTE
PASSAGE
PASSED SENATE
MESSAGE SENATE SENT TO HOUSE
Jul 12, 2024
RECEIVED IN CHAMBER
RECEIVED IN CHAMBER
Jul 15, 2024
RECEIVED IN CHAMBER
HELD AT DESK
Version
Font size
View Source View Markdown

Cost Estimates

1

Nonpartisan fiscal analysis from the Congressional Budget Office. Click any estimate to read the full report on cbo.gov.

Amendments

1
Amendment flow 1 merged from 1 voted amendments 1 terminal · 0 pending · 0 grouped below
1 passed 0 failed 0 ended
✓
SAMDT 2399 Merged
Jul 11, 2024 Full page
In the nature of a substitute.
Sponsor John Cornyn Republican
Voted amendment Accepted into the bill text passed · amendment passage